ReviewImmunology and allergy clinics of North America2017
Emerging Therapies in Hereditary Angioedema.
Review in Immunology and allergy clinics of North America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study.Allergy · 2021Trial
- Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks.Allergy · 2020Trial
- Long-Term Integrated Safety and Efficacy of Garadacimab for Hereditary Angioedema Prophylaxis.Advances in therapy · 2026Article
- Population Pharmacokinetic/Pharmacodynamic and Exposure-Response Modeling of Garadacimab in Healthy Volunteers and Patients With Hereditary Angioedema.CPT: pharmacometrics & systems pharmacology · 2025Article
- Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous and Intravenous Garadacimab Following Single-Dose Administration in Healthy Japanese and White Adults.Journal of clinical pharmacology · 2025Article
- Characteristics and Drug Utilization of Patients with Hereditary Angioedema in Italy, a Real-World Analysis.Healthcare (Basel, Switzerland) · 2023Article
- Could it be hereditary angioedema?-Perspectives from different medical specialties.Clinical and translational allergy · 2023Review
- Consensus on diagnosis and management of Hereditary Angioedema in the Middle East: A Delphi initiative.The World Allergy Organization journal · 2023Article
- Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.Journal of neurology · 2021Review
- Acute Presentation of Undiagnosed Hereditary Angioedema of the Larynx: Averting Death.Turkish archives of otorhinolaryngology · 2020Article
- Pregnancy-Induced Exacerbation of Hereditary Angioedema in a Multiparous Caucasian Female.Cureus · 2020Article
- IONIS-PKKNucleic acid therapeutics · 2019Article
- Article
- Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2019Review
Corrections and comments
- Erratum issuedErratum.2017
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Remarkable progress has been made in the treatment of bradykinin-mediated angioedema with the advent of multiple new therapies. Patients now have effective medications available for prophylaxis and treatment of acute attacks. However, hereditary angioedema is a burdensome disease that can lead to debilitating and dangerous angioedema episodes associated with significant costs for individuals and society. The burden of treatment must be addressed regarding medication administration difficulties, treatment complications, and adverse side effects. New therapies are being investigated and may offer solutions to these challenges. This article reviews the emerging therapeutic options for the treatment of HAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.